Clinical trials in Seattle, WA

286 recruiting studies have a site in or near Seattle, WA, Washington.

Top conditions here

All conditions

Showing 40 of 286 studies

RecruitingPhase 3NCT04047628

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Seattle, WA · +20 more sites

RecruitingPhase 3NCT03150693

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor: Alliance for Clinical Trials in Oncology

Aberdeen, WA · Bellevue, WA · Bellingham, WA · +452 more sites

RecruitingPhase 3NCT04267848

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Sponsor: National Cancer Institute (NCI)

Aberdeen, WA · Auburn, WA · Bellevue, WA · +1147 more sites

RecruitingPhase 1 / Phase 2NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Sponsor: Revolution Medicines, Inc.

Seattle, WA · +28 more sites

RecruitingPhase 2NCT06317662

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

Sponsor: National Cancer Institute (NCI)

Seattle, WA · Spokane, WA · +113 more sites

RecruitingPhase 3NCT06498635

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Sponsor: National Cancer Institute (NCI)

Edmonds, WA · Issaquah, WA · Seattle, WA · +278 more sites

RecruitingPhase 1NCT07304154

Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment

Sponsor: Kite, A Gilead Company

Seattle, WA · +4 more sites

RecruitingPhase 3NCT07525206

A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

Sponsor: AbbVie

Seattle, WA · +17 more sites

RecruitingPhase not listedNCT04706663

Precision-Based Genomics in Prostate Cancer

Sponsor: National Cancer Institute (NCI)

Seattle, WA · +10 more sites

RecruitingPhase 2NCT05554393

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Edmonds, WA · Issaquah, WA · Seattle, WA · +172 more sites

RecruitingPhase not listedNCT06297291

Global Paradise System US Post Approval Study

Sponsor: ReCor Medical, Inc.

Seattle, WA · +45 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Seattle, WA · Silverdale, WA · +52 more sites

RecruitingPhase 3NCT06819878

A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

Sponsor: Hoffmann-La Roche

Seattle, WA · Vancouver, WA · +93 more sites

RecruitingPhase 1 / Phase 2NCT07038343

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Sponsor: Avenzo Therapeutics, Inc.

Seattle, WA · +18 more sites

RecruitingPhase 1 / Phase 2NCT07061574

A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Sponsor: City of Hope Medical Center

Seattle, WA · +10 more sites

RecruitingPhase 3NCT07388524

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Sponsor: National Cancer Institute (NCI)

Edmonds, WA · Issaquah, WA · Seattle, WA · +97 more sites

RecruitingPhase 3NCT07674654

A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine

Sponsor: Kallyope Inc.

Seattle, WA · +112 more sites

RecruitingPhase 1NCT03460977

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Sponsor: Pfizer

Port Angeles, WA · Poulsbo, WA · Seattle, WA · +42 more sites

RecruitingPhase 1NCT06528301

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Sponsor: Umoja Biopharma

Seattle, WA · +6 more sites

RecruitingPhase 3NCT07011732

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Sponsor: Bristol-Myers Squibb

Seattle, WA · Spokane, WA · +39 more sites

RecruitingPhase 1 / Phase 2NCT07020221

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Sponsor: Verastem, Inc.

Seattle, WA · +12 more sites

RecruitingPhase 2NCT06317649

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Edmonds, WA · Issaquah, WA · Seattle, WA · +222 more sites

RecruitingPhase 3NCT06629779

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

Sponsor: Pfizer

Bonney Lake, WA · Federal Way, WA · Gig Harbor, WA · +36 more sites

RecruitingPhase 2NCT07610473

A Study to Evaluate the Effectiveness of DT-101 as an Adjunctive Treatment in Patients With Depression

Sponsor: Draig Therapeutics Ltd

Bellevue, WA · Seattle, WA · +21 more sites

RecruitingPhase not listedNCT02071134

Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry

Sponsor: Boston Scientific Corporation

Kirkland, WA · Seattle, WA · +26 more sites

RecruitingPhase 1 / Phase 2NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier

Seattle, WA · +20 more sites

RecruitingPhase 3NCT06136559

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

Sponsor: Merck Sharp & Dohme LLC

Edmonds, WA · Issaquah, WA · Seattle, WA · +46 more sites

RecruitingPhase 1 / Phase 2NCT06137118

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Sponsor: AstraZeneca

Seattle, WA · +11 more sites

RecruitingPhase 3NCT06307652

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

Sponsor: AstraZeneca

Puyallup, WA · Seattle, WA · Tacoma, WA · +163 more sites

RecruitingPhase 3NCT06430801

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

Sponsor: Merck Sharp & Dohme LLC

Bellevue, WA · Seattle, WA · +84 more sites

RecruitingPhase 3NCT06646276

A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Sponsor: Bristol-Myers Squibb

Edmonds, WA · Seattle, WA · +18 more sites

RecruitingPhase 2NCT06672146

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

Sponsor: National Cancer Institute (NCI)

Edmonds, WA · Issaquah, WA · Seattle, WA · +132 more sites

RecruitingPhase 3NCT06841354

A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

Sponsor: Merck Sharp & Dohme LLC

Seattle, WA · +38 more sites

RecruitingPhase 3NCT06966700

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Sponsor: Merck Sharp & Dohme LLC

Seattle, WA · Spokane, WA · Tacoma, WA · +61 more sites

RecruitingPhase 3NCT06989112

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Sponsor: AstraZeneca

Seattle, WA · +62 more sites

RecruitingPhase 3NCT07088068

A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes

Sponsor: Sanofi

Seattle, WA · Tacoma, WA · +32 more sites

RecruitingPhase 2NCT07187531

SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

Sponsor: SAb Biotherapeutics, Inc.

Seattle, WA · Tacoma, WA · +20 more sites

RecruitingPhase 3NCT07225504

A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

Sponsor: Novartis Pharmaceuticals

Seattle, WA · Spokane, WA · +41 more sites

RecruitingPhase 2NCT07322341

SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer

Sponsor: University of Washington

Seattle, WA

RecruitingPhase 2NCT07795814

A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)

Sponsor: Edgewise Therapeutics, Inc.

Seattle, WA · +27 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.